Aerovate Therapeutics Inc
AVTE · NASDAQ
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.
ESG Scores
Overall ESG5.0
Environmental6.5
Social3.7
Governance5.2
Gender Diversity
Female Directors0.2857%
CEO GenderMale